NASDAQ · OABI
OmniAb, Inc.
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
Loading market information…
NASDAQ · CCCC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
C4 Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
C4 Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow C4 Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$0.37+22.92% vs estimate | $7.20M+61.8% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.49-8.89% vs estimate | $5.18M+1.66% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | -$0.35+7.89% vs estimate | $15.40M+160.97% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$2.41-$0.12 (-4.74%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.1% below the high.
$3.53-$0.18 (-4.88%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
$1.22-$0.04 (-3.17%)
Codexis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
$3.25-$0.04 (-1.22%)
Armata Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.3% below the high.
$3.18$0.00 (0.0%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.63% below the high.
$0.79+$0.03 (+4.25%)
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
